Efficacy and Safety of Two Fixed-Dose Combinations of Tramadol Hydrochloride and Diclofenac Sodium in Postoperative Dental Pain.

Paul Desjardins, Fabian Alvarado, Martha Gil, Manuel González, Rogelio Guajardo

Journal: Pain medicine (Malden, Mass.) 2021;21(10):2447-2457

PMID: 32488263

Abstract

OBJECTIVE

To evaluate the analgesic efficacy and safety of tramadol hydrochloride/diclofenac sodium fixed-dose combination 25 mg/25 mg (FDC 25/25) and 50 mg/50 mg (FDC 50/50) vs tramadol 50 mg (T50) and diclofenac 50 mg (D50) monotherapies in acute postoperative dental pain.

SETTING

Eight sites across Mexico.

SUBJECTS

Adults (N = 829) with moderate to severe pain after third molar extraction.

DESIGN

Prospective, randomized, double-blind, diclofenac- and tramadol-controlled, parallel-group, noninferiority, phase 3 trial.

METHODS

Subjects were randomized to receive three doses (one every eight hours) of oral FDC 25/25, FDC 50/50, T50, or D50 over a 24-hour period. Pain intensity and pain relief were evaluated frequently over the 24 hours postdose. Secondary measures included peak pain relief, onset, and duration of effect. The primary objective was to compare the analgesic efficacy and safety of FDC 50/50 or analgesic noninferiority of FDC 25/25 vs D50 or T50. The primary efficacy end point was total pain relief over four hours after dose 1 (TOTPAR4).

RESULTS

TOTPAR4 scores showed that FDC 25/25 was noninferior (P < 0.0001, delta = 1.5) and FDC 50/50 was superior (P < 0.0001) to the individual components. All secondary efficacy measures supported these results. The safety profile of FDC 25/25 and FDC 50/50 was consistent with the known safety profile of D50 and T50 monotherapies, with no unexpected safety findings observed.

CONCLUSIONS

Tramadol/diclofenac FDC 25/25 and FDC 50/50 provide superior analgesia for acute pain after third molar extraction than either of the individual components. Minor adverse effects appeared to be related to the higher doses of tramadol.

© The Author(s) 2020. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: [email protected].

Address: Desjardins Associates, LLC, Maplewood, New Jersey.; Rutgers School of Dental Medicine, Newark, New Jersey, USA.; ECI-Estudios Clínicos Internacionales, Puebla, México.; Eukarya Pharmasite S.C., Monterrey, México.; Instituto de Investigación del Hospital Cardiológica, Aguascalientes, México.; Centro de Investigación Farmacológica del Bajío, S.C., León, Guanajuato, México.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.